Ceeto Capital Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Ceeto Capital Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.36M	Hold	4,756	–	–	0.64%	40
2026 Q1	$2.12M	Hold	4,756	–	–	0.65%	37
2025 Q4	$2.16M	Buy	4,756 +2,700	+131%	+$1.16M	0.63%	36
2025 Q3	$805K	Buy	+2,056	New	+$859K	0.23%	93
2021 Q3	–	Sell	-2,000	Closed	-$403K	–	157
2021 Q2	$403K	Hold	2,000	–	–	0.18%	109
2021 Q1	$430K	Buy	+2,000	New	+$439K	0.21%	99

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Ceeto Capital Group's VRTX Position: Q2 2026 in Review

Ceeto Capital Group held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 4,756 shares worth $2.36M. The position accounts for 0.64% of the portfolio, ranked #40.

Ceeto Capital Group first reported a position in VRTX in Q1 2021 and has held it in 6 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Ceeto Capital Group held 4,756 shares of Vertex Pharmaceuticals worth $2.36M as of Q2 2026.
Ceeto Capital Group left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.64% of Ceeto Capital Group's portfolio in Q2 2026, its #40 holding.
Ceeto Capital Group first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 6 quarters since.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Ceeto Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.